Vyvanse Compounding Legal Status: FDA Rules, DEA Restrictions, and What Patients Need to Know
Yes, lisdexamfetamine (Vyvanse) is a Schedule II controlled substance because it can be abused or lead to dependence. The FDA label has a boxed warning.
Vyvanse: Regulatory History
7 source-based articles maintained by the HealthRX.com Editorial Team.
7articles
4topic areas covered
May 25, 2026latest review
Vyvanse: Regulatory History library
Showing 7 of 7 clinical reviews.
Vyvanse EMA vs FDA Approach: Regulatory Differences Explained
A detailed comparison of how the FDA and EMA evaluated, labeled, and monitor lisdexamfetamine (Vyvanse), including approval dates, label differences, post-market surveillance programs, and what each means for prescribers and patients.
Vyvanse FAERS Safety Signals: What the Post-Market Data Actually Shows
A clinical deep-dive into Vyvanse (lisdexamfetamine) FAERS adverse event reports, FDA label warnings, and post-market surveillance data, prepared by the HealthRX.com Editorial Team.
Vyvanse FDA Approval History: Every Regulatory Milestone from 2007 to Generic Entry
A timeline of Vyvanse (lisdexamfetamine) FDA approvals, label expansions, safety updates, and generic entry, with sourcing notes on which claims are FDA-confirmed and which require primary-literature verification.
Vyvanse Global Regulatory Status: FDA Approval, International Scheduling, and Post-Market Surveillance
A comprehensive review of lisdexamfetamine (Vyvanse) regulatory status worldwide, including FDA approval history, EMA authorization, scheduling classifications, label updates, and ongoing safety monitoring.
Vyvanse Legal and Patent Challenges: FDA History, Litigation, and Generic Entry
A detailed review of Vyvanse (lisdexamfetamine) patent litigation, Hatch-Waxman challenges, FDA approval timeline, and the path to generic availability.
Vyvanse Pipeline and Next-Gen: FDA Approvals, Label Updates, and Post-Market Surveillance
A comprehensive look at lisdexamfetamine (Vyvanse) regulatory history, current FDA label, post-market safety data, and what the pipeline holds for next-generation ADHD and BED pharmacotherapy.